Our oral biotherapies are based on single-strain keystone bacteria. They aim to restore the missing functions of the gut microbiome to treat at a clinically relevant level life impacting diseases.
We use advanced full in-house isolation and characterization techniques to expand our unique strain collection.
Isolation using flow cytometry under anaerobic conditions, an innovative method recently published, is the highly innovative tool we co-develop with Bioaster.
Characterization goes through a full proprietary workflow of genetic, morphological, and biochemical assays using a mix wet-lab and bioinformatical methods. This step is in line with LBP regulatory expectations and allows a primary evaluation of the strain potential for therapeutic application.
Discover our related scientific publications:
YSOPIA is the first biotech to harness the therapeutic potential of Christensenella.
We have built the largest standardized collection of Christensenella strains worldwide, as well as a recognized know-how to advance specific strains of interest towards clinical development.
Preselected strains undergo an efficient screening process oriented toward therapeutical efficacy. A combination of in silico, in vitro and in vivo evaluation allows to select the best drug candidate to be pushed further into preclinical and clinical development.
Discover our related scientific publications:
Our added value is to rapidly run our drug candidate into patients while guaranteeing safety, efficacy and ensuring the rapid passage of our innovative biotherapies onto the market.
We gather unique expertise in single-strain Live Biotherapeutic Products development.
Thanks to our systematic and continuous exchanges with both US and European regulatory agencies, we have built a successful regulatory package for LBP development:
Discover our related scientific publications:
200m2 | 10 higly skilled people (PhD, PhD students, PharmD, Engineers, Engineers assistants)